tbuckley/cabot-search huggingface dataset:
Publisher Correction: Discovery of a genetic module essential for assigning left–right asymmetry in humans and ancestral vertebrates
Authors: Emmanuelle Szenker-Ravi, Tim Ott, Muznah Khatoo, Anne Moreau de Bellaing, Wei Xuan Goh, Yan Ling Chong, Anja Beckers, Darshini Kannesan, Guillaume Louvel, Priyanka Anujan, Vydianathan Ravi, Carine Bonnard, Sébastien Moutton, Patric Schoen, Mélanie Fradin, Estelle Colin, André Megarbane, Linda Daou, Ghassan Chehab, Sylvie Di Filippo, Caroline Rooryck, Jean-François Deleuze, Anne Boland, Nicolas Arribard, Rukiye Eker, Sumanty Tohari, Alvin Yu-Jin Ng, Marlène Rio, Chun Teck Lim, Birgit Eisenhaber, Frank Eisenhaber, Byrappa Venkatesh, Jeanne Amiel, Hugues Roest Crollius, Christopher T. Gordon, Achim Gossler, Sudipto Roy, Tania Attie-Bitach, Martin Blum, Patrice Bouvagnet, Bruno Reversade
Journal: Nature Genetics (2022)
The future of malaria control in light of RTS,S
Authors: Priya Venkatesan
Journal: The Lancet Microbe (2022)

The first antiparasitic RTS,S/AS01 (RTS,S) malaria vaccine, recommended by WHO in 2021 to be given to children living in regions with moderate-to-high transmission of Plasmodium falciparum malaria, is a huge step forward in the fight against malaria. However, many challenges remain for eliminating the disease. One such challenge is that the RTS,S vaccine is not expected to protect against the other human malaria parasites, namely Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, and the zoonotic Plasmodium knowlesi.
LUM015, A TRANSLATABLE MOLECULAR IMAGING AGENT, ENABLES OCT-NIRF IMAGING OF INFLAMMATORY PROTEASE ACTIVITY IN PRECLINICAL AND HUMAN ATHEROSCLEROSIS
Authors: Mohamad Kassab, Andrew Thrapp, Joseph A. Gardecki, Osman O. Ahsen, Yoichiro Kawamura, Adam Mauskapf, Graham Spicer, Evangelia Gavgiotaki, Aditya Kumar, Maya Modi, Ara L. Bablouzian, Paola Leon, Aidan Burbridge, Benjamin Childs, Guillermo Tearney, Farouc A. Jaffer
Journal: Journal of the American College of Cardiology (2022)
OUTCOMES OF VA-ECMO PLUS IABP VERSUS VA-ECMO ALONE FOR TREATMENT OF ACUTE MYOCARDIAL INFARCTION COMPLICATED BY CARDIOGENIC SHOCK:INSIGHT FROM THE JROADDPC REGISTRY
Authors: Takeshi Nishi, Masanobu Ishii, Kenichi Tsujita, Hiroshi Okamoto, Satoshi Koto, Michikazu Nakai, Yoko Sumita, Yoshitaka Iwanaga, Yoshio Kobayashi, Ken-ichi Hirata, Yutaka Hikichi, Hiroyoshi Yokoi, Yuji Ikari, Shiro Uemura
Journal: Journal of the American College of Cardiology (2022)
SEVERE SECONDARY MITRAL REGURGITATION FROM ATYPICAL INFERO-POSTERIOR TRUE LEFT VENTRICULAR ANEURYSM: A CARDIAC MULTIMODALITY IMAGING DIAGNOSIS
Authors: Alexander Griffith, Perry Wengrofsky, Amanda Meredith, Julius M. Gardin, Christine M. Gerula, Alfonso H. Waller
Journal: Journal of the American College of Cardiology (2022)
Exercise and Resistant Hypertension—Is Exercise Enough?
Authors: James A. Blumenthal, Andrew Sherwood, Alan L. Hinderliter
Journal: JAMA Cardiology (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Alterations of gut microbiota diversity, composition and metabonomics in testosterone-induced benign prostatic hyperplasia rats
Authors: Lu-Yao Li, Jie Han, Lan Wu, Cheng Fang, Wei-Guang Li, Jia-Min Gu, Tong Deng, Chang-Jiang Qin, Jia-Yan Nie, Xian-Tao Zeng
Journal: Military Medical Research (2022)

Abstract Background Studies had shown many diseases affect the stability of human microbiota, but how this relates to benign prostatic hyperplasia (BPH) has not been well understood. Hence, this study aimed to investigate the regulation of BPH on gut microbiota composition and metabonomics. Methods We analyzed gut samples from rats with BPH and healthy control rats, the gut microbiota composition and metabonomics were detected by 16S rDNA sequencing and liquid chromatography tandem mass spectrometry (LC–MS/MS). Results High-throughput sequencing results showed that gut microbiota beta-diversity increased ( P &lt; 0.01) in the BPH group vs. control group. Muribaculaceae ( P &lt; 0.01), Turicibacteraceae ( P &lt; 0.05), Turicibacter ( P &lt; 0.01) and Coprococcus ( P &lt; 0.01) were significantly decreased in the BPH group, whereas that of Mollicutes ( P &lt; 0.05) and Prevotella ( P &lt; 0.05) were significantly increased compared with the control group. Despite profound interindividual variability, the levels of several predominant genera were different. In addition, there were no statistically significant differences in several bacteria. BPH group vs. control group: Firmicutes (52.30% vs. 57.29%, P &gt; 0.05), Bacteroidetes (46.54% vs. 41.64%, P &gt; 0.05), Clostridia (50.89% vs. 54.66%, P &gt; 0.05), Ruminococcaceae (25.67% vs. 20.56%, P &gt; 0.05). LC–MS/MS of intestinal contents revealed that differential metabolites were mainly involved in cellular processes, environmental information processing, metabolism and organismal systems. The most important pathways were global and overview maps, lipid metabolism, amino acid metabolism, digestive system and endocrine system. Through enrichment analysis, we found that the differential metabolites were significantly enriched in metabolic pathways, steroid hormone biosynthesis, ovarian steroidogenesis, biosynthesis of unsaturated fatty acids and bile secretion. Pearson correlation analysis ( R = 0.94) showed that there was a strong correlation between Prevotellaceae , Corynebacteriaceae , Turicibacteraceae , Bifidobacteriaceae and differential metabolites. Conclusion Our findings suggested an association between the gut microbiota and BPH, but the causal relationship between the two groups is unclear. Thus, further studies are warranted to elucidate the potential mechanisms and causal relationships between BPH and gut microbiota.
SAFETY OF ALCOHOL SEPTAL ABLATION FOR SEPTAL REDUCTION PRIOR TO TRANSCATHETER MITRAL VALVE REPLACEMENT COMPARED TO OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
Authors: Mohamed Elhadi, Mayra E. Guerrero, Charanjit S. Rihal, Mackram F. Eleid
Journal: Journal of the American College of Cardiology (2022)
Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
Authors: Christine H. Chung, Jiannong Li, Conor E. Steuer, Priyanka Bhateja, Matthew Johnson, Jude Masannat, Maria I. Poole, Feifei Song, Juan C. Hernandez-Prera, Helen Molina, Bruce M. Wenig, Sunil Kumar, Charlotte Kuperwasser, Philip J. Stephens, Joaquim M. Farinhas, Dong M. Shin, Julie A. Kish, Jameel Muzaffar, Kedar Kirtane, James W. Rocco, Michael J. Schell, Nabil F. Saba, Marcelo Bonomi
Journal: Clinical Cancer Research (2022)

Abstract Purpose: A phase II multi-institutional clinical trial was conducted to determine overall survival (OS) in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) treated with a combination of cetuximab and nivolumab. Patients and Methods: Patients with R/M HNSCC were treated with cetuximab 500 mg/m2 i.v. on day 14 as a lead-in followed by cetuximab 500 mg/m2 i.v. and nivolumab 240 mg i.v. on day 1 and day 15 of each 28-day cycle. Expression of p16 and programmed cell death-ligand 1 (PD-L1) in archived tumors were determined. Tumor-tissue–modified human papillomavirus (TTMV) DNA was quantified in plasma. Results: Ninety-five patients were enrolled, and 88 patients were evaluable for OS with a median follow-up of 15.9 months. Median OS in the 45 patients who had prior therapy for R/M HNSCC (cohort A) was 11.4 months, with a 1 year OS 50% [90% confidence interval (CI), 0.43–0.57]. Median OS in the 43 patients who had no prior therapy (cohort B) was 20.2 months, with a 1-year OS 66% (90% CI, 0.59–0.71). In the combined cohorts, the p16-negative immunostaining was associated with higher response rate (RR; P = 0.02) but did not impact survival while higher PD-L1 combined positive score was associated with higher RR (P = 0.03) and longer OS (log-rank P = 0.04). In the p16-positive patients, lower median (1,230 copies/mL) TTMV DNA counts were associated with higher RR (P = 0.01) and longer OS compared with higher median (log-rank P = 0.05). Conclusions: The combination of cetuximab and nivolumab is effective in patients with both previously treated and untreated R/M HNSCC and warrants further evaluation.
lncRNA Linc00173 modulates glucose metabolism and multidrug chemoresistance in SCLC: Potential molecular panel for targeted therapy
Authors: Shuyu Wang, Fanrui Zeng, Shumei Liang, Qiuping Wang, Yang Wen, Qiongyao Wang, Jiexia Zhang, Man Li, Shun Fang, Ting Wei, Minglun Li, Farkhad Manapov, Jian Zhang, Linlang Guo
Journal: Molecular Therapy (2022)

(Molecular Therapy 30, https://doi.org/10.1016/j.ymthe.2021.11.003; April 6, 2022) Image analyses performed on western blot files used in in Figures 1I, 1J, 3F, S5B, and S6B of this article revealed evidence of image duplication and manipulation. Given these concerns, the editors and publisher are conducting an investigation to determine if a retraction is warranted. WITHDRAWN: lncRNA Linc00173 modulates glucose metabolism and multidrug chemoresistance in SCLC: Potential molecular panel for targeted therapyWang et al.Molecular TherapyNovember 7, 2021In BriefThis article has been withdrawn at the request of the editor-in-chief. Following publication of this article, the editor-in-chief discovered evidence of image duplication in Figures 1I, 1J, 3F, S5B, and S6B. Given the duplication of several western blots representing several gene products, the editor-in-chief has lost faith in the findings presented in this article. The authors maintain that these image duplications were the result of errors in file management and do not affect the conclusions of the study. Full-Text PDF lncRNA Linc00173 modulates glucose metabolism and multidrug chemoresistance inSCLC:Potentialmolecular panel for targeted therapy et al.Molecular TherapyJune 27, 2022In BriefThis article has been withdrawn at the request of the editor-in-chief. Full-Text PDF Open Archive
Abstract P5-14-15: Examining inequities related to inpatient hospital length of stay for breast cancer patients: A retrospective study during the COVID-19 pandemic
Authors: Sailaja Kamaraju, Bethany Canales, Tamiah Wright, John Charlson, Aniko Szabo, Thomas Wetzel, Steve Power, Grace Campbell
Journal: Cancer Research (2022)

Abstract Purpose: In the state of Wisconsin, breast cancer patients from African American (AAs) communities have lower survival rates compared to their Caucasian counterparts. Multiple inequities related to sociodemographic factors, delays in diagnosis, advanced disease stage at presentation and presence of comorbidities including higher body mass index (BMI) contribute to these disparities, many of which have only widened during the COVID-19 pandemic. This study examined specific factors related to prolonged hospital length of stay (LOS) for breast cancer patients admitted to inpatient units during the pandemic. Methods: This analysis includes initial CY20 LOS medical record data for hospitalized patients 18 years and older with a diagnosis of breast cancer from 1/1/2020-12/31/2020. Supplemental data included disease registry and diagnostic data, and SES data determined by patient zip code. Poisson regression models with robust standard errors were used to compare the LOS index (LOSi) between groups of patients based on race, SES group, primary payer, and BMI. Results: A total of 272 patients with breast cancer that were admitted to inpatient oncology units were identified. Demographics included White (72.4%), Black (22.4%), and others (5.1%). Other characteristics included: low SES (8.8%), medium- low (9.5%), medium (15.4%), medium-high (11.0%), high SES (4.4%), and others (non-Milwaukee county) (50.7%),Medicaid (8.8%), Medicare (61.3%), Managed care (29.0%), and others (0.73%). Body mass varied among the patients; underweight (0.36%), overweight (30.8%), obese (41.5%). There were significant differences in LOSi: Black (LOSi=1.24, p=0.01), medium-low SES (LOSi=1.46, p=0.02), Medicaid (LOSi=1.40, p=0.00), underweight (LOSi=1.66, p=0.00), and overweight (LOSi=1.23, p = 0.01) patients had slightly longer LOSi, with LOSi ratio above 1. Conclusion: This study shows how patient-specific factors such as race, SES, primary payer, and BMI contribute to inpatient LOS for breast cancer patients. Healthcare systems may benefit by addressing indicators and patients’ factors to reduce hospital LOS, and ultimately healthcare costs. Citation Format: Sailaja Kamaraju, Bethany Canales, Tamiah Wright, John Charlson, Aniko Szabo, Thomas Wetzel, Steve Power, Grace Campbell. Examining inequities related to inpatient hospital length of stay for breast cancer patients: A retrospective study during the COVID-19 pandemic [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P5-14-15.
PREVALENCE OF VALVULAR HEART DISEASE IN CARDIAC AMYLOIDOSIS AND IMPACT ON SURVIVAL
Authors: Esther Kwak, Iva Minga, Lucas Wathen, Safwan Gaznabi, Kifah Hussain, Victor Macrinici, Chi-Hsiung Wang, Nitasha Sarswat, Amit Pursnani
Journal: Journal of the American College of Cardiology (2022)
LOWER-EXTREMITY SYMPTOMS AND ANKLE-BRACHIAL INDEX SCREENING AS PREDICTORS OF CARDIOVASCULAR OUTCOMES IN BLACK ADULTS: INSIGHTS FROM THE JACKSON HEART STUDY
Authors: Megan Lee, Kim G.E. Smolderen, Kristie Harris, Gaelle Romain, Lindsey Scierka, Jeremy Provance, Carlos Mena-Hurtado
Journal: Journal of the American College of Cardiology (2022)
Lung targeted liposomes for treating ARDS
Authors: Sivan Arber Raviv, Mohammed Alyan, Egor Egorov, Agam Zano, Moshit Yaskin Harush, Calvin Pieters, Hila Korach-Rechtman, Adi Saadya, Galoz Kaneti, Igor Nudelman, Shai Farkash, Ofri Doppelt Flikshtain, Lucy N. Mekies, Lilach Koren, Yoav Gal, Ella Dor, Janna Shainsky, Jeny Shklover, Yochai Adir, Avi Schroeder
Journal: Journal of Controlled Release (2022)
Long-term Persistence of First-line Biologics for Patients With Psoriasis and Psoriatic Arthritis in the French Health Insurance Database
Authors: Laura Pina Vegas, Laetitia Penso, Pascal Claudepierre, Emilie Sbidian
Journal: JAMA Dermatology (2022)

Treatment options for psoriasis (PsO) and psoriatic arthritis (PsA) have evolved significantly throughout the era of biologics. Clinical trials are inadequate to assess the relative long-term efficacy of biologics and are often insufficient regarding safety.To assess the long-term persistence of different biologic classes to treat PsO and PsA.This nationwide cohort study involved the administrative health care database of the French health insurance scheme linked to the hospital discharge database. All adults with PsO and PsA who were new users of biologics (not in the year before the index date) from January 1, 2015, to May 31, 2019, were included and followed up through December 31, 2019. Patients hospitalized for PsA in the PsO cohort and for PsO in the PsA cohort in the year before the index date were excluded. Data were analyzed from June 1 to October 31, 2021.Persistence was defined as the time from biologic therapy initiation to discontinuation and was estimated using the Kaplan-Meier method. Comparison of persistence by biologic class involved using propensity score-weighted Cox proportional hazards regression models and adjustment on specific systemic nonbiologics (time-dependent variables).A total of 16 892 patients with PsO were included in the analysis (mean [SD] age, 48.5 [13.8] years; 9152 men [54.2%] men). Of these, 10 199 patients (60.4%) started therapy with a tumor necrosis factor (TNF) inhibitor; 3982 (23.6%), with an interleukin 12 and interleukin 23 (IL-12/23) inhibitor; and 2711 (16.0%), with an interleukin 17 (IL-17) inhibitor. An additional 6531 patients with PsA (mean [SD] age, 49.1 [12.8] years; 3565 [54.6%] women) were included; of these, 4974 (76.2%) started therapy with a TNF inhibitor; 803 (12.3%), with an IL-12/23 inhibitor; and 754 (11.5%), with an IL-17 inhibitor. Overall 3-year persistence rates were 40.9% and 36.2% for PsO and PsA, respectively. After inverse probability of treatment weighting and adjustment, the IL-17 inhibitor was associated with higher persistence compared with the TNF inhibitor for PsO (weighted hazard ratio [HR], 0.78 [95% CI, 0.73-0.83]) and PsA (weighted HR, 0.70 [95% CI, 0.58-0.85]) and compared with the IL-12/23 inhibitor for PsA (weighted HR, 0.69 [95% CI, 0.55-0.87]). No difference between the IL-17 inhibitor and IL-12/23 inhibitor for PsO was noted. The IL-12/23 inhibitor was associated with higher persistence than the TNF inhibitor for PsO (weighted HR, 0.76 [95% CI, 0.72-0.80]), with no difference observed for PsA.The findings of this cohort study suggest that IL-17 inhibitors are associated with higher treatment persistence than the TNF inhibitor for PsO and PsA. Interleukin 17 inhibitors were also associated with higher persistence than the IL-12/23 inhibitor for PsA, with no difference for PsO. However, the persistence rates of all biologics remained globally low at 3 years.
THE RELATIONSHIP OF AORTIC VALVE CALCIUM SCORE AND GLOMERULAR FILTRATION RATE IN PATIENTS WITH SEVERE AORTIC STENOSIS AND CHRONIC KIDNEY DISEASE
Authors: Ramy Mando, Amr E. Abbas, Olivia Allen, Brian M. Renard, Michael J. Gallagher, Francis Louis Shannon, Alessandro Vivacqua, Ivan Hanson
Journal: Journal of the American College of Cardiology (2022)
IMPACT OF SUPRAVENTRICULAR TACHYCARDIA ON OUTCOMES IN PATIENTS ADMITTED WITH ACUTE PULMONARY EMBOLISM
Authors: Dennis Danso Kumi, Irigbonse R. Asemota, Smirti Khanal, Bharosa Sharma, Emmanuel Akuna, Raquel Soon-Shiong, Muhammad Almani, Muhammad Usman
Journal: Journal of the American College of Cardiology (2022)
SAFETY AND EFFECTIVENESS OF THERMOCOOL STSF CATHETER FOR ABLATION OF ISCHEMIC VENTRICULAR TACHYCARDIA
Authors: Sanket Shishir Dhruva, Shumin Zhang, Jiajing Chen, Peter Noseworthy, Amit A. Doshi, Kolade Agboola, Jeph Herrin, Guoqian Jiang, Yue Yu, Guy Cafri, Kimberly Collison Farr, Keondae Ervin, Joseph S. Ross, Paul Coplan, Joseph P. Drozda
Journal: Journal of the American College of Cardiology (2022)
CLO22-053: Risk Factors of Paclitaxel Induced Peripheral Neuropathy in Early Breast Cancer Patient in Relation to Mean Changes of Neuropathy Growth Factors and Serum Malondialdehyde
Authors: Rasha Abo El Hassan, Noura Anwar Abdel-Fatah, Hadeer Khalefa Ahmed, May Shawki, Lamia El Wkeel
Journal: Journal of the National Comprehensive Cancer Network (2022)

"CLO22-053: Risk Factors of Paclitaxel Induced Peripheral Neuropathy in Early Breast Cancer Patient in Relation to Mean Changes of Neuropathy Growth Factors and Serum Malondialdehyde" published on 31 Mar 2022 by National Comprehensive Cancer Network.
In This Issue
Authors: Ruth Williams
Journal: Circulation Research (2022)

SARS-CoV-2 Infection Induces Ferroptosis of Sinoatrial Node Pacemaker Cells (p 963) SARS-CoV-2 can infect and kill the heart's pacemaker cells, report Han et al.A large proportion of patients hospitalized with COVID-19 develop abnormal heart rhythms.In fact, even patients with mild or moderate cases of the disease can experience temporary arrhythmia.To investigate the basis of this common symptom, Han and colleagues studied the hearts of hamsters infected with SARS-CoV-2, and found the virus attacked cells of the sinoatrial node (SAN)-better known as the heart's pacemaker.The virus could also infect human SAN-like cells, derived from embryonic stem cells, that expressed ACE2-the receptor used for virus entry.In these SAN-like cells, SARS-CoV-2 infection caused dysregulated calcium handling, increased production of reactive oxygen species and induction of a form of cell death called ferroptosis.Importantly, a screen of FDAapproved drugs led to the identification of deferoxamine and imatinib that, when used to treat the SAN-like cells, could prevent subsequent SARS-CoV-2 infection and associated ferroptosis.Imatinib, but not deferoxamine, could also reduce the number of SARS-CoV-2-infected cells when applied after the virus.Together, the results suggest a potential cause for the arrythmias experienced by some COVID-19 patients, and a possible pharmacological means to prevent them.
Do Glucocorticoid Injections Increase the Risk of Knee Osteoarthritis Progression Over 5 Years?
Authors: Augustin Latourte, Anne‐Christine Rat, Abdou Omorou, Willy Ngueyon‐Sime, Florent Eymard, Jérémie Sellam, Christian Roux, Hang‐Korng Ea, Martine Cohen‐Solal, Thomas Bardin, Johann Beaudreuil, Francis Guillemin, Pascal Richette
Journal: Arthritis & Rheumatology (2022)

Objective Recent findings have demonstrated that intraarticular (IA) glucocorticoid injections can be deleterious for knees with osteoarthritis (OA). This study was undertaken to assess, in a real‐life setting, the risk of knee OA progression in patients who received IA glucocorticoid injections over a 5‐year follow‐up period. Methods We used marginal structural modeling with inverse probability of treatment weighting to determine the causal association between IA glucocorticoid injections and the 5‐year risk of disease progression in patients with symptomatic knee OA from the Knee and Hip Osteoarthritis Long‐term Assessment cohort. OA progression was defined as an incident total knee replacement (TKR) and/or radiographic worsening (Kellgren/Lawrence [K/L] grade or joint space narrowing [JSN]). We also examined these outcomes in knees that received IA hyaluronan (IAHA) injections. Results Among the 564 patients with knee OA included in the study sample, 51 (9.0%) and 99 (17.5%) received IA glucocorticoid or IAHA injections, respectively, and 414 (63.1%) did not receive any injection during follow‐up. Compared to untreated knees, those treated with IA glucocorticoid injections had a similar risk of incident TKR (hazard ratio [HR] 0.92 [95% confidence interval (95% CI) 0.20, 4.14]; P = 0.91) or K/L grade worsening (HR 1.33 [95% CI 0.64, 2.79]; P = 0.44). IAHA injections had no effect on the risk of TKR (HR 0.81 [95% CI 0.14, 4.63]; P = 0.81) or K/L grade worsening (HR 1.36 [95% CI 0.85, 2.17]; P = 0.20). Similar results were obtained for JSN, and when TKR and radiographic outcomes were combined. Conclusion In this study, IA glucocorticoid injections for symptomatic knee OA did not significantly increase the 5‐year risk of incident TKR or radiographic worsening. These findings should be interpreted cautiously and replicated in other cohorts.